Kiniksa Pharmaceuticals Conference Call Summary Company Overview - **Company**: Kiniksa Pharmaceuticals International (NasdaqGS: KNSA) - **Event**: FY Conference on March 02, 2026 - **Key Speakers**: Sanj Patel (Chairman and CEO), Ross Moat (COO), John Paolini (CMO) Key Points Industry and Product Focus - **Primary Product**: ARCALYST, an IL-1 alpha and beta inhibitor for treating recurrent pericarditis - **Market Opportunity**: 18% penetration in the multiple recurrence patient group, with a total target market of 14,000 patients with multiple recurrences and an additional 26,000 patients experiencing their first recurrence [4][20][21] Financial Performance - **2025 Revenue**: Cumulative net revenue of $677.6 million, representing a 62% year-over-year growth [4] - **2026 Guidance**: Expected cumulative net revenue of $920 million, indicating continued growth [6] Growth Drivers - **Key Growth Factors**: - Increased patient additions and prescriber engagement - Higher rates of repeat prescriptions from physicians - Improved understanding of recurrent pericarditis as a chronic condition, leading to longer treatment durations [5][25] - Strong payer approval rates supporting commercial fundamentals [5] Marketing and Sales Strategy - **Sales Strategy**: Focus on digital marketing and AI initiatives to enhance prescriber education and patient engagement [19][36] - **Prescriber Engagement**: Over 4,150 unique prescribers identified, with a goal to reach the estimated 20,000-30,000 prescribers treating recurrent pericarditis [34] Treatment Paradigm Shift - **Changing Treatment Approaches**: Physicians are increasingly viewing recurrent pericarditis as a chronic condition requiring long-term treatment rather than episodic care [25][39] - **ARCALYST's Role**: Positioned as a preferred treatment option after NSAIDs and colchicine, especially for patients with severe symptoms or risk factors [39][40] Pipeline Developments - **KPL-387**: Phase 2 data expected in the second half of 2026, with plans to move into Phase 3 based on positive outcomes [59][60] - **KPL-1161**: Ongoing development with potential for indication expansion, though details remain undisclosed [72][74] Cash Flow and Investment Strategy - **Cash Utilization**: Focus on expanding KPL-387 and KPL-1161, while also considering potential acquisitions to enhance the portfolio [76][77] - **Pragmatic Approach**: The company emphasizes careful capital allocation and value creation, having successfully divested non-core assets in the past [77][78] Investor Insights - **Underappreciated Aspects**: The growth potential of KPL-387 and KPL-1161, along with the sustained success of ARCALYST, are highlighted as key areas that investors may overlook [79] Additional Considerations - **Q1 Expectations**: Anticipated headwinds due to payer plan changes and co-pay resets typical for the first quarter, which may impact gross-to-net revenue [28][31] - **Patient Characteristics**: Ongoing research into identifying patients who may benefit from early intervention with ARCALYST based on risk factors [51][52] This summary encapsulates the critical insights from the Kiniksa Pharmaceuticals conference call, focusing on the company's performance, strategic initiatives, and market opportunities.

Core Insights - The revenue growth of ARCALYST is projected at 62% for the full year 2025, driven by increased adoption of IL-1 alpha and beta inhibition as a second-line treatment after NSAID and colchicine failure [1] - Management credits the commercial success to a shift in treatment paradigms, supported by the 2025 ACC clinical guidance that endorses IL-1 inhibition as a preferred second-line approach [1] - The company is utilizing its profitable ARCALYST franchise to fund strategic investments in digital marketing, AI-driven physician targeting, and the development of internally discovered assets [1] Operational Focus - The operational focus has shifted towards unlocking the next phase of growth by increasing penetration in the multiple recurrence market and expanding into the first recurrence population [1] - Strategic positioning in the recurrent pericarditis market is being enhanced through the development of KPL-387, which aims to meet patient needs with less frequent monthly dosing and auto-injector administration [1] Market Dynamics - Market dynamics indicate that growth at specialized pericardial disease centers is outpacing other sites, leading management to explore ways to expand the impact of these high-volume centers [1]

Core Insights - Kiniksa Pharmaceuticals is focusing on expanding the adoption of ARCALYST for recurrent pericarditis, with plans for physician education and marketing initiatives to support earlier use in the disease course [1][4] - The company has set a net revenue guidance of $900 million to $920 million for 2026, despite facing seasonal headwinds in the specialty drug sector [2] - ARCALYST product revenue saw a significant increase of 65% year-over-year to $202.1 million in Q4 2025, contributing to a full-year revenue of $677.6 million, marking the highest year-on-year growth to date [3][14] Commercial Performance - The number of prescribers for ARCALYST exceeded 4,150 by the end of 2025, with approximately 29% prescribing it for two or more recurrent pericarditis patients [4] - Market penetration for the two-plus recurrence target market rose to about 18% by the end of 2025, up from 15% mid-year and 13% at the end of 2024 [5] - Approximately 20% of ARCALYST prescriptions are now written after a first recurrence, indicating a shift towards earlier treatment [6] Pipeline Developments - Kiniksa initiated a phase II/III clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with phase II data expected in the second half of 2026 [7][8] - KPL-387 aims to enhance market penetration through monthly dosing with an auto-injector, with 75% of recurrent pericarditis patients preferring its target product profile [11] - KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is expected to enter clinical trials by the end of 2026 [12] Financial Overview - Kiniksa reported a net income of $14.2 million in Q4 2025, a turnaround from a net loss of $8.9 million in the prior-year quarter, with a full-year net income of $59.0 million compared to a net loss of $43.2 million in 2024 [14] - Operating expenses increased due to higher costs associated with ARCALYST growth and investments in commercialization [13] - The company ended 2025 with $414.1 million in cash, indicating strong liquidity and a positive cash flow outlook [15]

Financial Data and Key Metrics Changes - ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [5][17] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for the full year 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with ARCALYST as a second-line treatment [9] - The average total duration of therapy for ARCALYST is approaching three years, with robust payer approval rates and strong patient adherence [12] Market Data and Key Metrics Changes - At the end of 2025, ARCALYST had over 4,150 prescribers, with around 29% prescribing for two or more recurrent pericarditis patients [11] - Penetration into the two-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for ARCALYST by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [7][54] - The company is focused on both ARCALYST and advancing its clinical portfolio to bring additional therapies to patients suffering from debilitating diseases [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of ARCALYST and the potential for KPL-387 to capture additional market share [5][9] - The company is optimistic about the future, emphasizing the importance of ongoing investments in R&D and commercialization efforts [6][20] Other Important Information - The company reported that ARCALYST revenue growth has been profitable since Q4 2021, allowing for strategic investments in sales and marketing [6] - The company expects to remain cash flow positive on an annual basis under its current operating plan [19] Q&A Session Summary Question: What do you think the peak penetration is for ARCALYST in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [23] Question: Is the pace of growth in first recurrence versus multiple recurrence patients the same? - The percentage of first recurrence patients has grown, and management views this as a positive change as physicians become more comfortable prescribing ARCALYST [29] Question: What is the extent of FDA interactions for KPL-387? - The company values its interactions with the FDA and has laid out a comprehensive development program for KPL-387 [38] Question: Are there differences in persistence rates between first recurrence and multiple recurrence populations? - No meaningful differences in persistence rates have been observed between the two populations [40] Question: How are you thinking about the enrollment curve for the phase III study of KPL-387? - Data from the Phase II portion of the trial is expected in the second half of 2026, with plans for a phase III study thereafter [46]

Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution F EB RUARY 24, 2026 Agenda Introduction | Sanj K. Patel, Chief Executive Officer IL-1α & IL-1β Inhibition Franchise | Ross Moat, Chief Operating Officer Fourth Quarter and Full Year 2025 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2 Forward Looking Statements This presentation (together with any other statements or information that we may make i ...

Core Insights - Kiniksa Pharmaceuticals reported significant growth in ARCALYST sales, achieving $677.6 million in net product revenue for the full year 2025, a 62% increase year-over-year [3][7] - The company expects ARCALYST net product revenue to reach between $900 million and $920 million in 2026 [3][12] - Kiniksa has a robust financial position with a cash balance of $414.1 million as of December 31, 2025, up from $243.6 million in 2024 [12][26] Financial Results - For Q4 2025, Kiniksa reported net product revenue of $202.1 million, compared to $122.5 million in Q4 2024 [7][8] - Total revenue for the full year 2025 was $677.6 million, an increase from $423.2 million in 2024 [12][23] - The company recorded a net income of $14.2 million for Q4 2025, a turnaround from a net loss of $8.9 million in Q4 2024, and a net income of $59.0 million for the full year 2025 compared to a net loss of $43.2 million in 2024 [12][23] Product Development - Kiniksa is advancing its clinical pipeline with KPL-387, a Phase 2/3 trial for recurrent pericarditis expected to yield data in the second half of 2026 [3][7] - The company plans to initiate a Phase 1 trial for KPL-1161 by the end of 2026, which is an Fc-modified monoclonal antibody targeting IL-1 receptor [5][12] Market Position - ARCALYST has become the preferred second-line treatment for recurrent pericarditis, contributing to its sales growth [3][4] - As of the end of Q4 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment, indicating strong market adoption [7][12]

Company Overview - Kiniksa has made significant progress in the development of ARCALYST for recurrent pericarditis, highlighting its commitment to addressing this medical condition [3] - The company is currently enrolling and dosing patients in a Phase II/III study for KPL-387, indicating ongoing research and development efforts [3] Leadership Insights - Sanj Patel, CEO and Chairman of the Board, expressed excitement about the company's advancements and future opportunities, reflecting a positive outlook on Kiniksa's trajectory [3]

Kiniksa Pharmaceuticals International FY Conference Summary Company Overview - **Company**: Kiniksa Pharmaceuticals International (NasdaqGS: KNSA) - **Focus**: Development and commercialization of treatments for recurrent pericarditis, particularly ARCALYST and KPL-387 Key Points Financial Performance - **2025 Net Revenue**: $677.5 million, representing a **62% year-over-year growth** [11] - **2026 Revenue Guidance**: Projected between **$900 million and $920 million** [12] Product Development and Pipeline - **ARCALYST**: - Positioned as a **second-line treatment** for recurrent pericarditis after NSAIDs and colchicine [12] - Cumulative net revenue since launch: **$1.5 billion** [11] - Market penetration in multiple recurrence patient group increased from **13% to 18%** from 2024 to 2025 [12] - Growing adoption in first recurrence patient group, with **20%** of patients prescribed ARCALYST during their first recurrence [13] - **KPL-387**: - Currently in a **Phase 2/3 study** for recurrent pericarditis, focusing on a **once-monthly dosing** regimen [5][8] - Expected to provide data from the dose-focusing portion in the **second half of 2026** [9] - Target product profile well-received by patients and healthcare professionals, with **75%** of surveyed patients preferring KPL-387 over current therapies [17] Market Dynamics - **Treatment Paradigm Shift**: - ARCALYST is becoming the **standard of care** for recurrent pericarditis, supported by the **ACC Concise Clinical Guidance** [14] - Increased utilization of ARCALYST has led to a decline in corticosteroid use as a second-line treatment [13] - **Commercial Strategy**: - Kiniksa has established a **cardiovascular-focused field team** and utilized AI-driven techniques to optimize outreach to physicians [15] - Growth in specialized pericardial disease centers from **2 to 18** since launch, enhancing patient care and treatment outcomes [16] Future Outlook - **Kiniksa's Strategy**: - Focused on maximizing current commercial opportunities while advancing clinical portfolio [18] - Strong financial position with **$414 million** in cash reserves at year-end, allowing for further investments [19] - **Physician Engagement**: - Significant growth in new prescribers, with **325 new prescribers** added in Q4 2025, totaling over **4,150 prescribers** [34] - Approximately **29%** of prescribers have treated two or more patients, indicating a positive trend towards repeat prescribing [35] Clinical Insights - **Epidemiology of Recurrent Pericarditis**: - Median duration of disease for patients with multiple recurrences is approximately **3 years**, with many patients requiring ongoing treatment [30] - Continuous therapy is essential to minimize flare rates, contrasting with episodic treatment approaches [33] Conclusion Kiniksa Pharmaceuticals is positioned for significant growth in the recurrent pericarditis market, driven by strong revenue performance, a robust pipeline, and a strategic focus on changing treatment paradigms. The company is well-capitalized to invest in future opportunities while enhancing patient care through innovative therapies.

Summary of Ventyx Biosciences FY Conference Call Company Overview - **Company**: Ventyx Biosciences (NasdaqGS: VTYX) - **Event**: FY Conference Call on December 03, 2025 Key Points Industry and Product Development - Ventyx is focused on developing VTX2735 for recurrent pericarditis (RP) and has announced a delay in data release to 1Q due to the need for additional patient data and formulation changes [1][2][4] - The company aims to transition to a once-daily (QD) dosing regimen, which is expected to enhance the drug's efficacy profile compared to the current twice-daily (BID) dosing [4][5] - The interim data cut has been postponed to allow for a more comprehensive understanding of the drug's efficacy and mechanism [6][10] Clinical Trial Design and Strategy - The original trial was designed for up to 30 patients, focusing on BID doses, but has been modified to include QD dosing to maximize data extraction [9][10] - The company has received approval to add more trial sites in Canada, the EU, and the UK, which will facilitate a smoother transition to phase 3 trials [6][24][25] - The engagement with regulatory agencies will occur once sufficient data is available, with a typical timeline of 6 to 9 months between phase 2 and phase 3 [23][24] Market Opportunity - The recurrent pericarditis market includes approximately 160,000 patients in the U.S., with 40,000 experiencing multiple recurrences annually [26][27] - ARCALYST, a competing product, is priced over $300,000 per year, providing Ventyx with significant pricing flexibility for its oral therapy [31][36] - The potential for VTX2735 to capture market share is bolstered by its oral administration compared to ARCALYST's infusion method [36] Competitive Landscape - VTX2735 must demonstrate a pain score reduction comparable to ARCALYST to be competitive, with a target pain score of zero or one [16][17] - The company is also exploring the potential for its NLRP3 portfolio in other indications, including cardiovascular diseases, while maintaining a focus on recurrent pericarditis [41][43] Financial and Strategic Position - Ventyx has seen significant stock performance, with a 700% increase over the past year, indicating strong investor interest [52] - The company is positioned to leverage its NLRP3 portfolio, with a focus on maintaining control over its development strategy while exploring partnerships for specific compounds [45][51] Conclusion - Ventyx Biosciences is strategically navigating the clinical development of VTX2735 while positioning itself in a lucrative market for recurrent pericarditis. The company is focused on optimizing its drug profile and expanding its clinical footprint, with a clear path toward phase 3 trials and potential market entry.

Summary of Kiniksa Pharmaceuticals International Conference Call Company Overview - Kiniksa Pharmaceuticals is a growth-oriented organization focused on developing novel therapies for debilitating diseases, particularly recurrent pericarditis [3][4][19] - The company has established leadership in the recurrent pericarditis market with its product ARCALYST, generating over $1 billion in net product revenue since FDA approval [3][4] Financial Performance - Kiniksa increased its net revenue guidance for 2025 to between $670 million and $675 million, reflecting strong commercial performance [4][19] - In Q3, Kiniksa reported $180.9 million in net product revenue for ARCALYST, a 61% year-over-year increase compared to Q3 2024 [5][19] - The company maintains a strong financial position with over $350 million in cash reserves [4][20] Market Penetration and Growth Opportunities - Kiniksa has only penetrated 15% of the multiple recurrence population, indicating significant growth potential [3][6] - Approximately 80% of ARCALYST prescriptions are for patients with two or more recurrences, while 20% are for patients on their first recurrence, up from 15% the previous year [5][6] - The company is focused on educating healthcare professionals about the chronic nature of recurrent pericarditis to improve patient retention on treatment [28][29] Pipeline Development - KPL-387, a new drug in development for recurrent pericarditis, received orphan drug designation from the FDA and is currently in a phase 2/3 clinical trial [4][19] - The phase 2 portion of the trial is expected to read out in the second half of 2026, with the goal of launching KPL-387 by 2028-2029 [4][18] - KPL-387 is designed for monthly dosing and aims to provide a highly efficacious and well-tolerated treatment option [14][35] Physician and Patient Engagement - Kiniksa is working to ensure a positive prescribing experience for physicians, which is expected to lead to repeat prescriptions and peer-to-peer education [8][9] - The company has expanded the number of specialized care centers for pericardial diseases from 2 to 18 in collaboration with the American Heart Association [9][10] - Market research indicates that over 75% of patients would choose KPL-387 as their preferred treatment option, and more than 90% of healthcare professionals would likely prescribe it [11][35] Conclusion - Kiniksa is well-positioned for future success with a robust strategy to maximize the commercial opportunity of ARCALYST and advance its clinical portfolio [19][20] - The company is committed to addressing the unmet needs of patients suffering from recurrent pericarditis through innovative therapies and strong market engagement strategies [3][4][19]